Ross Michael A. 4

What Happened

• Ross Michael, a director of 20/20 Biolabs, had 31 shares of Series A-2 preferred stock automatically converted into 31 shares of common stock on February 19, 2026. The common shares were recorded as acquired at $0.00 per share (a non-cash corporate conversion), and the corresponding 31 preferred-share derivative position was cancelled/converted.

Key Details

• Transaction date: 2026-02-19; Filing date (Form 4): 2026-02-23 (filed within the two-business-day deadline).
• Reported entries: Acquisition of 31 common shares at $0.00 (conversion C); simultaneous disposition of 31 derivative preferred shares (derivative conversion).
• Shares owned after transaction: Not specified in the provided excerpt of the Form 4.
• Footnote: The conversion was automatic upon the company’s common stock listing on the Nasdaq Capital Market; the Series A-2 preferred had no expiration date (Footnote F1).
• No purchase/sale cash transaction occurred—this was a corporate conversion, not a market buy or sale.

Context

• This was a shareholder-preferred-to-common conversion tied to the company’s Nasdaq listing rather than an insider buying or selling for investment reasons. Such conversions are administrative/corporate events and generally should not be interpreted as a trading signal by themselves.